Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04721899

Vitamin D and Endometrial Receptivity in Infertile Women

Effect of Vitamin D on Vaginal / Endometrial Biomarkers and Endometrial Receptivity in Women With Fertility Problems

Status
Recruiting
Phase
Study type
Observational
Enrollment
105 (estimated)
Sponsor
The University of Hong Kong · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

This is a prospective study comparing vaginal and endometrial biomarkers and the trophoblast spheroid attachment rate in women with fertility problems before and after taking Vitamin D for 8 weeks.

Detailed description

The aim of this study is to assess the effect of vitamin D supplementation on vaginal / endometrial biomarkers and endometrial receptivity in women with fertility problems. Women will have vaginal swab and endometrial biopsy twice. The first endometrial biopsy is performed using a Pipelle sampler 7 days after luteinizing hormone surge (LH+7) at baseline and the attachment rate of the trophoblast spheroid onto the isolated endometrial epithelial cells will be assessed to assess endometrial receptivity at baseline. Implantation biomarkers will be checked. They will take Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks. After 8 weeks of Vitamin D, a second vaginal swab and endometrial biopsy using a Pipelle sampler by standard technique will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared. The laboratory staff will not know whether the patient is taking any vitamin D when performing the trophoblast spheroid attachment assay/ biomarkers.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTVitamin DVitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks

Timeline

Start date
2021-01-15
Primary completion
2025-02-01
Completion
2026-08-01
First posted
2021-01-25
Last updated
2024-05-14

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT04721899. Inclusion in this directory is not an endorsement.